SENSEX NIFTY

Tablets

Jul 20, 2016 at 17:50 | Source: PTI
The approval granted by the USFDA to three domestic firms for generic rosuvastatin calcium tablets are for strengths of 5 mg, 10 mg, 20 mg and 40 mg.
Jul 20, 2016 at 17:50 | Source: PTI
The USFDA had earlier given approval to market a generic version of Janssen Pharmaceuticals, Inc.'s Ortho Tri-Cyclen tablets in the same strengths, it added.
Jul 20, 2016 at 15:29 | Source: Moneycontrol.com
Lupin has launched its Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg / 0.035 mg, 0.215 mg / 0.035 mg and 0.25 mg / 0.035 mg having received an approval from the USFDA earlier to market a generic version of Janssen Pharmaceuticals, Inc.'s Ortho Tri-Cyclen Tablets.
Jul 20, 2016 at 12:10 | Source: PTI
In a BSE filing, Sun Pharma said: "One of its subsidiaries has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Crestor, Rosuvastatin Calcium tablets.
Jul 20, 2016 at 12:00 | Source: Moneycontrol.com
Aurobindo Pharma, Glenmark and Sun Pharmaceutical gained 2-4 percent intraday after the US health regulator has given approval for antihyperlipidemic drug Rosuvastatin calcium tablets.
Jul 20, 2016 at 11:57 | Source: Moneycontrol.com
Sun Pharma announced that one of its subsidiaries has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Crestor, Rosuvastatin Calcium tablets 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base).
Jul 20, 2016 at 11:30 | Source: PTI
"The company has received final approval by the US Food and Drug Administration (US FDA) for Rosuvastatin Calcium tablets," Aurobindo Pharma said in a BSE filing.
Jul 20, 2016 at 11:15 | Source: Moneycontrol.com
"....has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rosuvastatin calcium tablets, 5 mg, 10 mg, 20 mg and 40 mg," says Hyderabad-based Aurobindo in its filing.
Jul 20, 2016 at 11:12 | Source: PTI
"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (US FDA) for rosuvastatin calcium tablets," it said in a BSE filing.
Jul 20, 2016 at 09:59 | Source: Moneycontrol.com
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rosuvastatin Calcium Tablets, 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base).
Messages on Tablets »

madrasan

Silver Member

1 Followers

Shasun Pharma  

a license to sell a generic version of Renvela (sevelamer carbonate) 800-mg tablets beginning March 16, 2014. Impax can also sell oral suspension versions of Renvela and Renagel (sevelamer hydrochloride) beginning September 16, 2014.

12.48 PM Jul 8th 2014

BSE/NSE Announcer

Platinum Member

15197 Followers

Glenmark  

Glenmark Pharmaceuticals Limited has informed the Exchange regarding the press release dated July 08, 2014 titled,"Glenmark Generics receives final ANDA approval for Telmisartan Tablets."

12.41 PM Jul 8th 2014

BSE/NSE Announcer

Platinum Member

15197 Followers

Glenmark  

Glenmark Generics Inc., USA a subsidiary of Glenmark Generics has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Telmisartan Tablets. Glenmark will commence distribution of the product immediately.

12.04 PM Jul 8th 2014

BSE/NSE Announcer

Platinum Member

15197 Followers

Glenmark  

Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 08, 2014 titled "Glenmark Generics receives final ANDA approval for Telmisartan Tablets" Glenmark Generics Inc., USA a subsidiary of Glenmark Generics has been granted final abbreviated new drug approval (ANDA) from

12.04 PM Jul 8th 2014

phs25

Gold Member

9 Followers

Glenmark  

Glenmark Generics receives final ANDA approval for Telmisartan Tablets | 07/08/14 12:01 Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 08, 2014 titled "Glenmark Generics receives final ANDA approval for Telmisartan Tablets

12.03 PM Jul 8th 2014

aindia

Silver Member

211 Followers

Ybrant Digital  

% growth for the first time since 2004, when ad spending increased 6.7%. Mobile will lead this year’s rise in total media ad spending in the US, and advertisers will spend 83.0% more on tablets and smartphones than they did in 2013—an increase of $8.04 billion. By the end of this year, mobile

7.34 PM Jul 2nd 2014

Web Messenger

Platinum Member

356181 Followers

Mobile Tele  

Source:VC Circle - Samsung-Galaxy-Tab-S After unveiling the same last month, Samsung has now launched its Galaxy Tab S range of tablets in the Indian market. The tablets are available in 8.4 and 10.5 inch display screen sizes and according to the company, these are the ...

3.16 PM Jul 2nd 2014

Web Messenger

Platinum Member

356181 Followers

Mobile Tele  

Source:Money Rediff News Report - Sony's flagship tablet - the Xperia Z2 Tablet - after going on sale in some parts of the world, has now become available in India at an online retailer at a price of Rs. 49,990 for its 4G LTE variant. The tablet is also listed on the official website

3.16 PM Jul 2nd 2014

Web Messenger

Platinum Member

356181 Followers

Mobile Tele  

Source:Money Rediff News Report - Korean electronics giant Samsung today launched its new tablet 'Tab S' for Rs 37,800 onwards, to further strengthen its position in the Indian market. The device will be available in two screen sizes - 8.4 inch and 10.5 inch - priced at Rs 37,800 and

3.16 PM Jul 2nd 2014

Web Messenger

Platinum Member

356181 Followers

News Now  

Source:Economic Times - Hybrids and Detachables When Microsoft launched Windows 8 with a touch-optimized interface, a number of manufacturers launched hybrid and detachable devices that offered the benefit of a traditional laptop as well as a tablet. These hybrids are easy to carry around, have

3.12 PM Jul 2nd 2014

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.